| Remdesivir in patients with acute or chronic kidney disease and COVID-19 ML Adamsick, RG Gandhi, MR Bidell, RH Elshaboury, RP Bhattacharyya, ... Journal of the American Society of Nephrology 31 (7), 1384-1386, 2020 | 201 | 2020 |
| Fluoroquinolone‐associated tendinopathy: does levofloxacin pose the greatest risk? MR Bidell, TP Lodise Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 36 (6 …, 2016 | 89 | 2016 |
| Fluoroquinolone and third-generation-cephalosporin resistance among hospitalized patients with urinary tract infections due to Escherichia coli: do rates vary by hospital … MR Bidell, M Palchak, J Mohr, TP Lodise Antimicrobial agents and chemotherapy 60 (5), 3170-3173, 2016 | 66 | 2016 |
| Desirable characteristics of hepatitis C treatment regimens: a review of what we have and what we need MR Bidell, M McLaughlin, J Faragon, C Morse, N Patel Infectious diseases and therapy 5, 299-312, 2016 | 49 | 2016 |
| Colistin nephrotoxicity: meta-analysis of randomized controlled trials K Eljaaly, MR Bidell, RG Gandhi, S Alshehri, MA Enani, A Al-Jedai, ... Open forum infectious diseases 8 (2), ofab026, 2021 | 48 | 2021 |
| Characterization of the haematological profile of 21 days of tedizolid in healthy subjects TP Lodise, MR Bidell, SD Flanagan, EJ Zasowski, SL Minassian, ... Journal of Antimicrobial Chemotherapy 71 (9), 2553-2558, 2016 | 48 | 2016 |
| Optimal treatment of MSSA bacteraemias: a meta-analysis of cefazolin versus antistaphylococcal penicillins MR Bidell, N Patel, JN O’Donnell Journal of Antimicrobial Chemotherapy 73 (10), 2643-2651, 2018 | 44 | 2018 |
| Baseline procalcitonin as a predictor of bacterial infection and clinical outcomes in COVID-19: A case-control study NJ Atallah, HM Warren, MB Roberts, RH Elshaboury, MR Bidell, ... PLoS One 17 (1), e0262342, 2022 | 34 | 2022 |
| Approach to the Treatment of Patients with Serious Multidrug‐Resistant Pseudomonas aeruginosa Infections JN O'Donnell, MR Bidell, TP Lodise Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 40 (9 …, 2020 | 32 | 2020 |
| Effect of prior receipt of antibiotics on the pathogen distribution and antibiotic resistance profile of key Gram-negative pathogens among patients with hospital-onset urinary … MR Bidell, MP Opraseuth, M Yoon, J Mohr, TP Lodise BMC infectious diseases 17, 1-7, 2017 | 28 | 2017 |
| Gut microbiome health and dysbiosis: A clinical primer MR Bidell, ALV Hobbs, TP Lodise Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 42 (11 …, 2022 | 25 | 2022 |
| Suboptimal clinical response rates with newer antibiotics among patients with moderate renal impairment: review of the literature and potential pharmacokinetic and … MR Bidell, TP Lodise Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 38 (12 …, 2018 | 25 | 2018 |
| Use of oral tetracyclines in the treatment of adult outpatients with skin and skin structure infections: Focus on doxycycline, minocycline, and omadacycline MR Bidell, TP Lodise Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 41 (11 …, 2021 | 18 | 2021 |
| Relationship between vancomycin exposure and outcomes among patients with MRSA bloodstream infections with vancomycin Etest® MIC values of 1.5 mg/L: a pilot study DM Martirosov, MR Bidell, MP Pai, MH Scheetz, SL Rosenkranz, ... Diagnostic microbiology and infectious disease 88 (3), 259-263, 2017 | 18 | 2017 |
| Use of oral tetracyclines in the treatment of adult patients with community-acquired bacterial pneumonia: a literature review on the often-overlooked antibiotic class MR Bidell, MAP Pai, TP Lodise Antibiotics 9 (12), 905, 2020 | 17 | 2020 |
| Relationship between day 1 and day 2 Vancomycin area under the curve values and emergence of heterogeneous Vancomycin-intermediate Staphylococcus aureus (hVISA) by Etest … DM Martirosov, MR Bidell, MP Pai, MH Scheetz, SL Rosenkranz, ... BMC Infectious Diseases 17, 1-7, 2017 | 12 | 2017 |
| Clinical safety and tolerability of tedizolid phosphate in the treatment of acute bacterial skin and skin structure infections C Hardalo, TP Lodise, M Bidell, S Flanagan, C De Anda, S Anuskiewicz, ... Expert Opinion on Drug Safety 17 (4), 359-367, 2018 | 11 | 2018 |
| Remdesivir use and outcomes during the FDA COVID-19 emergency use authorization period RH Elshaboury, MM Monk, LM Bebell, MR Bidell, ML Adamsick, ... Therapeutic Advances in Infectious Disease 8, 20499361211046669, 2021 | 7 | 2021 |
| A case series of rifabutin use in staphylococcal prosthetic infections M Monk, R Elshaboury, A Tatara, S Nelson, MR Bidell Microbiology Spectrum 10 (3), e00384-22, 2022 | 3* | 2022 |
| Fidaxomicin-associated hypersensitivity reactions: report of a morbilliform drug eruption RR Molleti, MR Bidell, AW Tatara Journal of Pharmacy Practice 36 (4), 993-997, 2023 | 2 | 2023 |
